doc.ai, an advanced natural language processing technology platform for quantified biology announced the successful completion of its initial sale of Simple Agreements for future tokens (SAFTs). A total of ten purchasers acquired SAFTs, consisting of institutional and other accredited investors, for an aggregate purchase amount of approximately $2.3 million.
The early pre-sale of doc.ai’s SAFTs, which are convertible into digital tokens named Neurons (NRNs), was limited to existing investors and advisors who have either helped support doc.ai in the past or have demonstrated the desire to partner and support the Neuron Network.
Pantera Capital anchored the offering as the lead investor.
“We are excited to be the lead investor in the early SAFT offering by doc.ai. The company offers an unparalleled innovative technology solution at the intersection of blockchain and artificial intelligence.”
The presale to eligible investors of SAFTs to acquire doc.ai’s Neuron (NRN) tokens, based on the ERC-20 standard began last week. The crowdsale process is expected to start on September 28th, 2017.
“I am amazed by the potential that doc.ai technology has for millions of people all over the world and possible network effects of the NRN token. I am looking forward to exploring potential synergies between doc.ai and Jaxx.”
The solicitation, offer, and sale of SAFTs in all phases will be conducted in a manner that is compliant with applicable securities laws and regulations, including Rule 506(c) of Regulation D. In the United States, only verified accredited investors will be eligible to purchase SAFTs.
doc.ai was founded by the entrepreneurial duo Walter and Sam De Brouwer in 2016. The Palo Alto, California, company has raised seed funding from Comet Labs, F50, Legend Star and S2 Capital, and already has several prominent clients.
“The initial pre-sale demonstrates for doc.ai the confidence of these investors. We believe that artificial intelligence is poised to revolutionize health care and drastically improve patients’ care and experience, and our investors have proven their adherence to our vision.”